Yellow fever prophylaxis when vaccination is not an option
- Funded by Netherlands Organisation for Health Research and Development (ZonMW)
- Total publications:0 publications
Grant number: 1.015E+13
Grant search
Key facts
Disease
Yellow FeverStart & end year
2024.02025.0Known Financial Commitments (USD)
$0Funder
Netherlands Organisation for Health Research and Development (ZonMW)Principal Investigator
Dr. Anna RoukensResearch Location
NetherlandsLead Research Institution
Leids Universitair Medisch CentrumResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Prophylactic use of treatments
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
Yellow fever is caused by the yellow fever virus, which is endemic in Africa and South America. The disease can be deadly and there is no treatment available. A vaccine exists which gives lifelong protection, but during an outbreak the vaccine stockpile is often insufficient, due to the complex production process. Meanwhile, due to climate change, there is an increasing risk of the expansion of yellow fever virus to Europe. For travellers to endemic countries vaccination is often mandatory, but contraindicated for those who are immunocompromised and used restrictively in persons older than 60, as the yellow fever vaccine is a live attenuated viral vaccine with the potential of causing a severe infection that mimics yellow fever. Recently a medicine that is used to treat hepatitis C infection (sofosbuvir) has shown to cure mice with yellow fever. Approach/working method We will investigate the efficacy of sofosbuvir in a human infection model as prophylaxis against yellow fever in 30 healthy participants.